Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: A pilot control-case study in Colombian Hispanic women
暂无分享,去创建一个
Julien Wist | Jessica Medina | J. Wist | Roland J W Meesters | Mónica P Cala | Julian Aldana | Julián Sánchez | José Guio | J. Medina | R. Meesters | José Guio | Mónica P. Cala | Julian Aldana | Julián Sánchez | Jessica Medina
[1] H. Degani,et al. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. , 1996, Anticancer research.
[2] H. Degani,et al. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. , 1996, Anticancer research.
[3] J. Erickson,et al. Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism? , 2010, Oncotarget.
[4] H. Baloglu,et al. Alterations of serum lipids and lipoproteins in breast cancer. , 1994, Cancer letters.
[5] H. Gerstein,et al. Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells , 2011, BMC Cancer.
[6] James Ze Wang,et al. Perioperative dynamics and significance of amino acid profiles in patients with cancer , 2015, Journal of Translational Medicine.
[7] Matej Oresic,et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. , 2011, Cancer research.
[8] Yang Liu,et al. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction , 2008, Molecular Cancer Therapeutics.
[9] Takashi Ishikawa,et al. Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.
[10] D. Rose,et al. Omega-3 fatty acids as cancer chemopreventive agents. , 1999, Pharmacology & therapeutics.
[11] C. Townsend,et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Dwivedi,et al. Total Cholesterol and Triglyceride Levels in Patients with Breast Cancer , 2013, Journal of breast cancer.
[13] Yong-Ho Ahn,et al. Up-regulation of Acetyl-CoA Carboxylase α and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells* , 2007, Journal of Biological Chemistry.
[14] Phenotyping human blood plasma by 1H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer , 2015, Metabolomics.
[15] Youping Deng,et al. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions , 2016, Oncotarget.
[16] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[17] M. Ogawa,et al. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. , 1994, British Journal of Cancer.
[18] Scha.. Lipotoxicity: when tissues overeat , 2003 .
[19] A. Habenicht,et al. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? , 2006, International journal of cancer.
[20] Kristian Hovde Liland,et al. Multivariate methods in metabolomics – from pre-processing to dimension reduction and statistical analysis , 2011 .
[21] Robert Powers,et al. Multivariate Analysis in Metabolomics. , 2012, Current Metabolomics.
[22] V. Vance,et al. BRIEF COMMUNICATION Plasma amino acid profiles of breast cancer patients early in the trajectory of the disease differ from healthy comparison , 2014 .
[23] E. Jobard,et al. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. , 2014, Cancer letters.
[24] R. Matsunuma,et al. Human Breast Cancer Tissues Contain Abundant Phosphatidylcholine(36∶1) with High Stearoyl-CoA Desaturase-1 Expression , 2013, PloS one.
[25] Guang Chen,et al. Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients. , 2016, Biomedical chromatography : BMC.
[26] W. Negendank,et al. Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.
[27] P. Morris,et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] J. Wist,et al. Coffee's country of origin determined by NMR: the Colombian case. , 2015, Food chemistry.
[29] J. Schaffer,et al. Lipotoxicity: when tissues overeat , 2003, Current opinion in lipidology.
[30] M. Dutta,et al. Comprehensive quantitative lipidomic approach to investigate serum phospholipid alterations in breast cancer , 2016, Metabolomics.
[31] Y. Yen,et al. Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer Patients , 2013, International journal of molecular sciences.
[32] V. Vance,et al. Plasma amino acid profiles of breast cancer patients early in the trajectory of the disease differ from healthy comparison groups. , 2014, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[33] Song Liu,et al. Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes. , 2013, Translational oncology.
[34] J. Chang,et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. , 2011, Chemistry & biology.
[35] D Y Noh,et al. Expression of phospholipase C-gamma 1 and its transcriptional regulators in breast cancer tissues. , 1998, Anticancer research.
[36] Coral Barbas,et al. In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting. , 2012, Analytical chemistry.
[37] S. Husain,et al. Role of lipids, lipoproteins and vitamins in women with breast cancer. , 2001, Clinical biochemistry.
[38] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[39] A. Toker,et al. Nonessential amino acid metabolism in breast cancer. , 2016, Advances in biological regulation.
[40] Jianping Chen,et al. Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine , 2014, Evidence-based complementary and alternative medicine : eCAM.
[41] Rupasri Mandal,et al. Cancer Metabolomics and the Human Metabolome Database , 2016, Metabolites.
[42] M. Arbushites,et al. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study , 2012, Molecular oncology.
[43] S. Majid,et al. Serum Lipid Profile of Breast Cancer Patients in Kashmir , 2013 .
[44] Z. Bhujwalla,et al. Choline phospholipid metabolism: A target in cancer cells? , 2003, Journal of cellular biochemistry.
[45] Tanja Fehm,et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.
[46] Age K. Smilde,et al. Assessing the performance of statistical validation tools for megavariate metabolomics data , 2006, Metabolomics.
[47] Nissi M. Varki,et al. Ras activation in human breast cancer , 2000, Breast Cancer Research and Treatment.
[48] Y. Chun,et al. Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials , 2016, Oncotarget.
[49] Y. Fujiwara. Cyclic phosphatidic acid - a unique bioactive phospholipid. , 2008, Biochimica et biophysica acta.
[50] S. Ambs,et al. Metabolic signatures of human breast cancer , 2015, Molecular & cellular oncology.
[51] D. Im,et al. Action and Signaling of Lysophosphatidylethanolamine in MDA-MB-231 Breast Cancer Cells , 2014, Biomolecules & therapeutics.
[52] C A Halterman,et al. Controlling quality. , 1982, Quintessence of dental technology.
[53] C. Clarke,et al. Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden , 2014, Metabolomics.
[54] Lian‐Wen Qi,et al. Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer , 2016, Oncotarget.
[55] M. Gross,et al. Quantification of diacylglycerol molecular species in biological samples by electrospray ionization mass spectrometry after one-step derivatization. , 2007, Analytical chemistry.
[56] Yan Xu,et al. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. , 2002, Biochimica et Biophysica Acta.
[57] Andrew D. Southam,et al. Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics , 2016, Metabolomics.
[58] C. Barbas,et al. Metabolomic approach with LC-MS reveals significant effect of pressure on diver's plasma. , 2010, Journal of proteome research.
[59] R. Clarke,et al. Application of Metabolomics in Drug Resistant Breast Cancer Research , 2015, Metabolites.
[60] Zhili Li,et al. In situ characterizing membrane lipid phenotype of breast cancer cells using mass spectrometry profiling , 2015, Scientific Reports.
[61] Feng Zhang,et al. Dysregulated lipid metabolism in cancer. , 2012, World journal of biological chemistry.
[62] P. Querzoli,et al. Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. , 2007, Carcinogenesis.
[63] S. Narod,et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia , 2014, Hereditary Cancer in Clinical Practice.
[64] Y. Nishizuka. Protein kinase C and lipid signaling for sustained cellular responses , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[65] C. McCulloch,et al. Associations between breast cancer, plasma triglycerides, and cholesterol. , 1991, Nutrition and cancer.
[66] M. Spraul,et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. , 2014, Analytical chemistry.
[67] Coral Barbas,et al. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics. , 2011, Methods in molecular biology.
[68] C. Townsend,et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase , 2000 .
[69] P. Domingues,et al. Lipidomic analysis of phospholipids from human mammary epithelial and breast cancer cell lines , 2013, Journal of cellular physiology.
[70] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[71] B. Faubert,et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. , 2011, Genes & development.
[72] M. King,et al. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.
[73] S. Sethi,et al. Recent advances in lipidomics: Analytical and clinical perspectives. , 2017, Prostaglandins & other lipid mediators.
[74] G. Kong,et al. Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry , 2009, Analytical and bioanalytical chemistry.
[75] P. Maini,et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer , 2007, British Journal of Cancer.
[76] C. Barbas,et al. Metabolomics in cancer biomarker discovery: current trends and future perspectives. , 2014, Journal of pharmaceutical and biomedical analysis.
[77] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[78] Jose M. Silva,et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.
[79] M. Mourtada-Maarabouni,et al. Inhibition of Human T-Cell Proliferation by Mammalian Target of Rapamycin (mTOR) Antagonists Requires Noncoding RNA Growth-Arrest-Specific Transcript 5 (GAS5) , 2010, Molecular Pharmacology.
[80] Arnald Alonso,et al. Analytical Methods in Untargeted Metabolomics: State of the Art in 2015 , 2015, Front. Bioeng. Biotechnol..
[81] B. El-Gamal,et al. Serum lipids and tissue DNA content in Egyptian female breast cancer patients. , 2003, Japanese journal of clinical oncology.
[82] Coral Barbas,et al. Controlling the quality of metabolomics data: new strategies to get the best out of the QC sample , 2015, Metabolomics.
[83] T. Powles,et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.
[84] I. Wilson,et al. Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[85] F. Podo. Tumour phospholipid metabolism , 1999, NMR in biomedicine.
[86] D. Wishart. Emerging applications of metabolomics in drug discovery and precision medicine , 2016, Nature Reviews Drug Discovery.
[87] D. Rose,et al. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. , 1998, International journal of oncology.
[88] A. Molinari,et al. Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells , 2012, Breast Cancer Research.
[89] U. Hamann,et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia , 2007, Breast Cancer Research and Treatment.
[90] Daniel Raftery,et al. Early detection of recurrent breast cancer using metabolite profiling. , 2010, Cancer research.
[91] C. Zielinski,et al. Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer , 2004, Journal of Cancer Research and Clinical Oncology.
[92] Peiyuan Yin,et al. Current state-of-the-art of nontargeted metabolomics based on liquid chromatography-mass spectrometry with special emphasis in clinical applications. , 2014, Journal of chromatography. A.
[93] S. Choi,et al. Lipid profiles for HER2-positive breast cancer. , 2013, Anticancer research.
[94] Yu Bai,et al. Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers , 2015, Analytical and Bioanalytical Chemistry.
[95] Z. Bhujwalla,et al. Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.
[96] C. I. D. Vargas,et al. Análisis de las mutaciones más frecuentes del gen BRCA1 (185delAG y 5382insC) en mujeres con cáncer de mama en Bucaramanga, Colombia , 2009 .
[97] Hong-Shiee Lai,et al. Plasma free amino acid profile in cancer patients. , 2005, Seminars in cancer biology.
[98] U. Günther. Metabolomics Biomarkers for Breast Cancer , 2015, Pathobiology.
[99] D. Page,et al. BRCA1 and BRCA2 hereditary breast carcinoma phenotypes , 1997 .
[100] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[101] J. Winnike,et al. Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. , 2016, Journal of proteome research.
[102] S. Eckhardt,et al. Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.
[103] Stacy D. Sherrod,et al. Untargeted Metabolomics Strategies—Challenges and Emerging Directions , 2016, Journal of The American Society for Mass Spectrometry.
[104] Oliver Fiehn,et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study , 2012, BMC Genomics.
[105] Jie Chen,et al. Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.
[106] M. Spraul,et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.
[107] Y. Mechref,et al. Elevated levels of hydroxylated phosphocholine lipids in the blood serum of breast cancer patients. , 2009, Rapid communications in mass spectrometry : RCM.
[108] Robert V Farese,et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[109] Jianguo Xia,et al. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst , 2011, Nature Protocols.
[110] D. Noh,et al. Overexpression of phospholipase D1 in human breast cancer tissues. , 2000, Cancer letters.
[111] Tongshu Yang,et al. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. , 2012, Clinical biochemistry.
[112] Y. Gong,et al. Link between obesity and cancer: role of triglyceride/free fatty acid cycling. , 2014, European review for medical and pharmacological sciences.